Affibody Ab

General Electric Company

Abclon Inc.

Fredrik Frejd

Elin Gunneriusson

Joachim Feldwisch

Lindvi Gudmundsdotter

Rong Zhang

Faisal Ahmed Syud

Lars B Abrahmsen

Christofer Lendel

Brian Duh-Lan Lee

Nina Herne

Paul Schaffer

Peter Brian Iveson

Susanne Klint

Tove Simonsson

Caroline Ekblad

John Löfblom

Malin Lindborg

Lars Abrahmsén

Stefan Stahl

Andreas Jonsson

Stefan Ståhl

Tove Eriksson

Torbjörn Gräslund

Mikaela Friedman

Johan Seijsing

Per-Åke Nygren

Vladimir Tolmachev

Per-Ake Nygren

Ingmarie Höidén-Guthenberg

Amelie Eriksson Karlström

Joel Lindgren

Nina Kronqvist

Feifan Yu

Lars ABRAHMSÉN

Lars Abrahmsen

Faisal Syud

John Lofblom

Torbjorn Graslund

Peter Iveson

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-17A (IL-17A), and provides an IL-17A binding polypeptide comprising the sequence EXDXAXXEIXXLPNL XXXQXXAFIXXLXX. Also disclosed is the use of such an interleukin-17A binding polypeptide as a diagnostic, prognostic and/or therapeutic agent.

Methods of treatment of IL-17A associated conditions

Imaging agents comprising an isolated polypeptide conjugated with a radionucleide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

HER2 binders

IL-17A-binding polypeptides

Imaging agents comprising an isolated polypeptide conjugated with a radionuclide and a chelator; wherein the isolated polypeptide binds specifically to HER2, or a variant thereof; and methods for preparing and using these imaging agents.

The present disclosure relates to a class of engineered polypeptides having a binding affinity for interleukin-6, and provides an IL-6 binding polypeptide comprising the sequence EEXXAWXEIH XLPNLXXXQXXAFIXXLXX. The present disclosure also relates to the use of such an IL-6 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.

Polypeptide

The present disclosure relates to complex comprising an engineered polypeptide having affinity for interleukin-6 (in the following referred to as IL-6) and an antibody or an antigen binding fragment thereof, wherein said engineered polypeptide having affinity for IL-6 belongs to a class of engineered polypeptides comprising the sequence EEXXAWXEIHXLPN-LXXXQXXAFIXXLXX. The present disclosure also relates to the use of said complex as a therapeutic agent.

IL-6-binding polypeptide complex

The present disclosure relates to dimers of engineered polypeptides having a binding affinity for the neonatal Fc receptor FcRn, and provides an FcRn binding dimer, comprising a first monomer unit, a second monomer unit and an amino acid linker, wherein the first and second monomer units each comprises an FcRn binding motif. The FcRn binding dimer binds FcRn with higher capacity compared to the first monomer unit or second monomer unit alone. The present disclosure also relates to the use of the FcRn binding dimer as an agent for modifying pharmacokinetic and pharmacodynamic properties and as a therapeutic agent.

Neonatal Fc receptor binding dimer and methods of use

The disclosure provides a HER3 binding polypeptide, comprising a HER3 binding motif, BM, which motif consists of the amino acid sequence selected from i) EXXXA XXEIW XLPNL XXXQXXAFIXXLXD, and ii) an amino acid sequence which has at least 90% identity to the sequence defined in i), wherein the polypeptide binds to the extra-cellular domain of HER3. Also provided is a bispecific ligand having binding affinity for HER3 and for HER2, or for HER3 and for EGFR, and comprising a HER3. binding polypeptide as defined herein and a HER2 binding polypeptide or a EGFR binding polypeptide.

HER3 binding polypeptides

The present disclosure relates to a class of engineered polypeptides having a binding affinity for albumin. In particular, the present invention relates to albumin binding polypeptides which have a high resistance to proteolytic cleavage and therapeutic use thereof. The disclosure provides an albumin binding polypeptide comprising an albumin binding motif, which motif consists of the amino acid sequence 

Engineered albumin binding polypeptide

This invention relates to polypeptides which bind to EGFR family receptors and to applications of those polypeptides in medicine, veterinary medicine, diagnosis, diagnostics, and imaging.

Polypeptides

Growing community of inventors

Stockholm, Sweden

Fredrik Frejd